MCPIP1 Endoribonuclease Activity Negatively Regulates Interleukin-17-Mediated Signaling and Inflammation  by Garg, Abhishek V. et al.
ArticleMCPIP1 Endoribonuclease Activity Negatively
Regulates Interleukin-17-Mediated Signaling and
InflammationGraphical AbstractHighlightsd MCPIP1 (Regnase-1) is a feedback inhibitor of IL-17 signal
transduction
d MCPIP1 deficiency enhances immunity to fungi but
exacerbates pathology in EAE
d MCPIP1 impairs activation of certain IL-17 target promoters
by degrading IkBz mRNA
d MCPIP1 degrades transcripts encoding IL-17R subunits
independently of the 30 UTRGarg et al., 2015, Immunity 43, 475–487
September 15, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.immuni.2015.07.021Authors
Abhishek V.Garg, Nilesh Amatya, Kong
Chen, ..., Mandy J. McGeachy,
Pappachan E. Kolattukudy, Sarah L.
Gaffen
Correspondence
sarah.gaffen@pitt.edu
In Brief
Interleukin-17 (IL-17) induces pathology
in autoimmunity and infections and
therefore its activity must be tightly
regulated. Gaffen and colleagues report
that the endoribonuclease MCPIP1
degrades IL-17-induced transcripts,
including Il6 and Nfkbiz (Ikbz), to
negatively regulate IL-17 receptor
signaling both in fungal immunity and
experimental autoimmune
encephalomyelitis.
Immunity
ArticleMCPIP1 Endoribonuclease Activity
Negatively Regulates Interleukin-17-Mediated
Signaling and Inflammation
Abhishek V. Garg,1 Nilesh Amatya,1 Kong Chen,2 J. Agustin Cruz,1 Prerna Grover,3 Natasha Whibley,1 Heather R. Conti,1
Gerard Hernandez Mir,1 Tatiana Sirakova,4 Erin C. Childs,1 Thomas E. Smithgall,3 Partha S. Biswas,1 Jay K. Kolls,2
Mandy J. McGeachy,1 Pappachan E. Kolattukudy,4 and Sarah L. Gaffen1,*
1Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA
2Department of Pediatrics & Immunology, Richard King Mellon Institute for Pediatric Research, University of Pittsburgh School of Medicine,
Pittsburgh, PA 15224, USA
3Department of Microbiology & Molecular Genetics, University of Pittsburgh, Pittsburgh, PA 15261, USA
4Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA
*Correspondence: sarah.gaffen@pitt.edu
http://dx.doi.org/10.1016/j.immuni.2015.07.021SUMMARY
Interleukin-17 (IL-17) induces pathology in auto-
immunity and infections; therefore, constraint of this
pathway is an essential component of its regulation.
We demonstrate that the signaling intermediate
MCPIP1 (also termed Regnase-1, encoded by
Zc3h12a) is a feedback inhibitor of IL-17 receptor
signal transduction. MCPIP1 knockdown enhanced
IL-17-mediated signaling, requiringMCPIP1’s endori-
bonuclease but not deubiquitinase domain. MCPIP1
haploinsufficient mice showed enhanced resistance
to disseminated Candida albicans infection, which
was reversed in an Il17ra/ background. Conversely,
IL-17-dependent pathology in Zc3h12a+/ mice was
exacerbated in both EAE and pulmonary inflamma-
tion. MCPIP1 degraded Il6 mRNA directly but only
modestly downregulated the IL-6 promoter. However,
MCPIP1 strongly inhibited theLcn2promoter by regu-
lating the mRNA stability of Nfkbiz, encoding the IkBz
transcription factor.Unexpectedly,MCPIP1degraded
Il17ra and Il17rc mRNA, independently of the 30 UTR.
The cumulative impact of MCPIP1 on IL-6, IkBz, and
possibly IL-17R subunits results in a biologically rele-
vant inhibition of IL-17 signaling.
INTRODUCTION
IL-17 (IL-17A) is the signature cytokine of Th17 cells and is also
produced by innate immune cells (Cua and Tato, 2010). IL-17-
deficient individuals experience recurrent fungal and bacterial in-
fections caused by Candida and Staphylococcal species (Milner
and Holland, 2013). Conversely, IL-17 is a major driver of auto-
immunity, and antibodies targeting IL-17 or its receptor are
showing promise in treating psoriasis and other disorders (Patel
et al., 2013).
IL-17 and its receptor, a heterodimer of IL-17RA and IL-17RC,
are all members of a distinct class of cytokines (Gaffen et al.,Im2014). Both subunits contain a motif known as SEFIR (SEF
and IL-17R) domain, which engages the only known SEFIR-con-
taining adaptor, Act1. Act1 recruits and ubiquitinates TRAF6,
activating downstream NF-kB, CCAAT/Enhancer Binding Pro-
tein (C/EBP), and Mitogen Activated Protein Kinase (MAPK)
pathways. IL-17-induced targets include cytokines (IL-6, G-
CSF), antimicrobial peptides (S100A8/9, lipocalin-2, b-defen-
sins), transcription factors (C/EBPd, IkBz), and neutrophil-re-
cruiting chemokines (CXCL1, CXCL2, CXCL5). In addition to
stimulating transcription, IL-17 controls stabilization of mRNA
transcripts through RNA binding proteins such as SF2 and
HuR (Herjan et al., 2013; Sun et al., 2011). Thus, IL-17 signal-
ing upregulates a program of gene expression that controls
infection.
Dysregulated inflammation causes collateral tissue damage,
ultimately resulting in lymphoproliferative disorders or autoim-
munity. This process is well studied for TNF and IL-1 signaling
but is poorly defined for IL-17. Recently, several checkpoints
have been identified that restrict IL-17 activity. The deubiquiti-
nases (DUBs) A20 and USP25 negatively regulate IL-17-induced
NF-kB andMAPK activation by removing ubiquitin modifications
on TRAF6 (Garg et al., 2013; Zhong et al., 2012). Additionally, IL-
17 suppresses expression of miR-23b, a microRNA that limits
NF-kB activation by targeting TAB2, TAB3, and IKKa (Song
and Qian, 2013; Zhu et al., 2012). IL-17 also induces phosphor-
ylation of C/EBPb, a transcription factor that inhibits IL-17-
dependent gene expression (Shen et al., 2009).
In an effort to discover new regulators of IL-17 signal transduc-
tion, we evaluated archival microarray data for potential IL-17-
dependent signaling modulators. Zc3h12a (encoding MCPIP1;
also known as Regnase-1) was identified in a screen of IL-
17RA-dependent genes involved in antifungal immunity (Conti
et al., 2009). This gene is also induced in fibroblasts or macro-
phages treated with IL-17 (Dhamija et al., 2013; Sønder et al.,
2011). MCPIP1 is expressed at low levels in most cell types
but is upregulated by inflammatory stimuli such as MCP-1, IL-
1b, and TLR ligands (Jura et al., 2012). MCPIP1 is an endoribo-
nuclease (RNase) that inhibits TLR signaling by degrading
mRNA transcripts such as Il6 through a 30 UTR stem-loop
motif (Matsushita et al., 2009; Mino et al., 2015). IL-6 is a down-
stream gene target of IL-17 signaling and contributes to manymunity 43, 475–487, September 15, 2015 ª2015 Elsevier Inc. 475
Figure 1. MCPIP1 Is a Feedback Inhibitor of IL-17 Signaling
(A) RNA from WT or Il17ra/ tongues (n = 3) were collected 48 hr after oral infection with PBS (sham) or C. albicans. Expression of Zc3h12a was assessed by
qPCR and normalized to Gapdh. *p < 0.05 versus sham.
(B) OKF6/TERT2 oral keratinocytes were treated ± IL-17 and mRNA analyzed for ZC3H12A by qPCR. Data presented as fold change versus unstimulated (0 hr);
*p < 0.05 versus untreated.
(C) ST2 cells were incubated ± IL-17 and mRNA was analyzed by qPCR, normalized toGapdh. Inset: Lysates from ST2 cells treated ± IL-17 were immunoblotted
for MCPIP1 or b-tubulin. Data presented as fold change versus unstimulated.
(D and E) ST2 cells were transfected with siRNAs against Act1, MCPIP1, or a scrambled control. Cells were treated ± IL-17 for 3 hr. Supernatants were assessed
by ELISA (left). Il6 and Lcn2 were assessed by qPCR. *p < 0.05 versus IL-17-treated siRNA control; zp < 0.05 versus untreated. Data presented as fold change
relative to untreated siRNA control.
(F) Zc3h12a/ fibroblasts were transfected with an empty vector or a plasmid encoding murineMCPIP1. Cells were treated with IL-17 for 4 hr, and IL-6 assessed
by ELISA. *p < 0.05 versus IL-17-treated controls.
(G) Primary fibroblasts from Zc3h12a+/ or WT littermates were treated with IL-17 for 24 hr and IL-6 assessed by ELISA.*p < 0.05 versus IL-17-treated controls.
zp < 0.05 versus untreated.
Data presented as mean ± SEM throughout. All experiments were performed a minimum of twice.IL-17-mediated inflammatory events (Camporeale and Poli,
2012). In addition to its RNase functions, MCPIP1 exhibits
DUB activity that blocks TLR-activation of TRAFs (Liang et al.,
2010; Niu et al., 2013). In vivo, MCPIP1 is a negative regulator
of TLR and TCR signaling (Liang et al., 2010; Uehata et al.,
2013) and limits Th17 cell differentiation (Jeltsch et al., 2014).
We show that MCPIP1 is a direct inhibitor of IL-17-mediated
signal transduction. MCPIP1 deficiency enhanced IL-17-depen-
dent resistance toCandida albicans infection and also increased
pathology in experimental autoimmune encephalomyelitis (EAE).
These effects were associated with suppressed expression of
IL-6, Lipocalin 2, IkBz, and other IL-17 target genes. In addition
to its capacity to degrade mRNA, we found that MCPIP1 regu-
lates certain IL-17-dependent promoters through control of476 Immunity 43, 475–487, September 15, 2015 ª2015 Elsevier Inc.IkBz. Lastly, MCPIP1 can induce decay of mRNA transcripts en-
coding inflammatory receptors, including IL-17R subunits.
RESULTS
MCPIP1 Is a Feedback Inhibitor of IL-17 Signaling
Mice and humans lacking the IL-17 receptor are susceptible to
C. albicans infection (Milner and Holland, 2013). We observed
that Zc3h12a was rapidly induced after oropharyngeal candidi-
asis (OPC) in WT but not Il17ra/ mice (Figure 1A; Conti et al.,
2009). Consistently, ZC3H12A was induced by IL-17 in human
oral keratinocytes (Figure 1B; Dickson et al., 2000). In ST2 cells,
a murine stromal cell line, expression of Zc3h12a was enhanced
within 30 min of IL-17 stimulation and remained 5- to 6-fold
elevated for at least 24 hr. MCPIP1 protein expression was
increased with similar kinetics (Figure 1C).
To determine whether MCPIP1 impacts IL-17 signaling, ST2
cells were transfected with siRNAs targeting MCPIP1, Act1, or
a scrambled control. Efficiency of knockdown was 50%–70%
(Figures S1A and S1B). Cells were treated with IL-17 for 3 hr,
and IL-6 was assessed in conditioned media. As expected,
Act1 knockdown inhibited IL-17-induced production of IL-6 (Fig-
ure 1D). In contrast, knockdown of MCPIP1 increased IL-17-
dependent IL-6 secretion and Il6 mRNA (Figure 1D). MCPIP1
knockdown also increased basal expression of IL-6, revealing
a role in regulating tonic cytokine expression. Because Il6 is a
known target of MCPIP1 (Matsushita et al., 2009), we evaluated
additional IL-17-dependent genes to assess specificity. Simi-
larly, Csf3 (G-CSF) was enhanced upon MCPIP1 knockdown
(Figure S1A). Unlike Il6, IL-17 induction of Lcn2 (lipocalin 2) is
not controlled at the level of mRNA stability (Shen et al., 2006).
Nonetheless, MCPIP1 knockdown increased IL-17-dependent
expression of Lcn2 (Figure 1E). To rule out off-target effects of
siRNA, Zc3h12a/ fibroblasts were transfected with a plasmid
containing MCPIP1 or a control vector. Reconstitution of
Zc3h12a/ cells led to reduced IL-6 expression in response to
IL-17 (Figure 1F). Consistently, fibroblasts from Zc3h12a+/
and Zc3h12a/ mice showed enhanced induction of IL-6 in
response to IL-17 (Figures 1G, S1C, and S1D). Thus, MCPIP1
is a feedback inhibitor of IL-17 signaling in non-hematopoietic
cells.
MCPIP1 Inhibits IL-17 Signaling in Pulmonary
Inflammation
Zc3h12a/ mice exhibit severe inflammation due to unre-
strained TLR signaling from intestinal microbiota (Liang et al.,
2010; Matsushita et al., 2009; Miao et al., 2013). Because
these mice survive only 6–8 weeks, they were unsuitable for
experimentation. However, Zc3h12a+/ mice are healthy, fertile,
and exhibit normal lifespans. There was no detectable baseline
inflammation in visceral organs (lungs or kidneys) of unmani-
pulated Zc3h12a+/ mice determined by expression of inflam-
matory cytokines (Figure S2), though they showed mild inflam-
mation in gut (data not shown). Moreover, fibroblasts from
Zc3h12a+/ mice showed reduced expression of MCPIP1 upon
treatment with inflammatory stimuli such as LPS and IL-17,
whereas baseline levels were similar to Zc3h12a+/+ (Figure 2A).
These findings raised the possibility that Zc3h12a+/mice might
have impaired control of inflammation in settings where MCPIP1
is normally induced (namely, IL-17 signaling).
To determine whether MCPIP1 haploinsufficiency led to
enhanced IL-17 activity in vivo, Zc3h12a+/ or Zc3h12a+/+ litter-
mates were challenged intranasally with IL-17 to induce pulmo-
nary inflammation. After 24 hr, bronchoalveolar lavage fluid
(BALF) was evaluated for cellular influx and IL-17-dependent
inflammation. The number and percentage of Gr1+F4/80 infil-
trating neutrophils in Zc3h12a+/ BALF were elevated compared
to Zc3h12a+/+ (Figures 2B and 2C). Histology confirmed en-
hanced inflammation in Zc3h12a+/ lungs (Figure 2D). Consis-
tent with elevated neutrophil infiltration, there was also increased
amounts of CXCL5 in the BALF, although CXCL1 concentrations
were unchanged at this time point (Figure 2E). Notably, no T cells
were recruited to lung in this setting (J.K.K., unpublished data).ImThese results demonstrate that Zc3h12a+/ mice exhibit an
elevated capacity for IL-17 responsiveness.
MCPIP1 Deficiency Enhances IL-17-Mediated
Resistance to Fungal Infection
Because IL-17 drives immunity toC. albicans (Huang et al., 2004;
Saijo et al., 2010), we postulated that elevated IL-17 signaling in
Zc3h12a+/ mice would improve fungal clearance. Accordingly,
mice were inoculated i.v. with C. albicans, and kidney fungal
loads were assessed after 2 days. Zc3h12a+/ mice exhibited
a 2-log lower renal fungal load than Zc3h12a+/+ mice (Figure 3A)
and markedly prolonged survival (Figure 3B). PAS staining con-
firmed the presence of invasive Candida hyphae in Zc3h12a+/+
but not Zc3h12a+/ kidneys (Figure 3C). To verify that the
reduced fungal load in Zc3h12a+/ mice was IL-17 dependent,
Zc3h12a+/ mice were crossed to Il17ra/ mice and subjected
to candidiasis. As previously shown (Huang et al., 2004),
Il17ra/ mice exhibited 1-log higher fungal burden than WT
(Figure 3A). Strikingly, Zc3h12a+/Il17ra/ mice were unable
to control infection, with a renal fungal load 2.5-log greater
than Zc3h12a+/ and indistinguishable from Il17ra/ mice
(Figure 3A). Zc3h12a+/Il17ra/ mice also exhibited decreased
survival in response to infection (Figure S2C). Therefore, the
reduced Candida susceptibility in Zc3h12a+/ mice is due to
enhanced IL-17 signaling.
IL-6 is one of the best characterized IL-17 target genes and
contributes to immunity to candidiasis (Basu et al., 2008).
Accordingly, if the entire protective effect of MCPIP1 were due
to IL-6, IL-6 neutralization would be expected to reverse disease
susceptibility. To test this hypothesis, Zc3h12a+/+ or Zc3h12a+/
micewere administered neutralizing Abs against IL-6R (Wu et al.,
2013) and infected with C. albicans. As expected, blocking IL-6
increased fungal loads in both Zc3h12a+/+ and Zc3h12a+/
mice (Figure 3D). However, anti-IL-6R Abs did not fully reverse
the protection in Zc3h12a+/ animals, suggesting that IL-6 is
not the sole IL-17-dependent mediator of disease protection.
This is consistent with findings that no change in tonic inflamma-
tion occurs in Zc3h12a/Il6/ mice (Uehata et al., 2013).
MCPIP1 Deficiency Enhances EAE
IL-17 drives pathology in EAE, so we predicted that Zc3h12a+/
mice would show enhanced CNS inflammation due to unre-
strained IL-17 signaling. Mice were immunized with myelin oligo-
dendrocyte (MOG) in CFA and administered one dose of
pertussis toxin to cause mild clinical EAE. Il17ra/ mice were
resistant to EAE, whereas Zc3h12a+/mice showed dramatically
increased clinical scores, with earlier disease onset and higher
incidence (Figure 4A). These events were IL-17 dependent, as
indicated by the fact that Zc3h12a+/Il17ra/ mice exhibited
reduced EAE symptoms compared to Zc3h12a+/ mice. Spinal
cord showed enhanced expression of IL-17 target genes known
to contribute to EAE, including Il6, Cxcl1, and Csf2 (Figure 4B).
Thus, MCPIP1 constrains autoimmune pathology driven by
IL-17.
MCPIP1 Regulates Nfkbiz mRNA Stability
IL-17 upregulates IL-6 expression by control of mRNA stability
and by activating its proximal promoter (Ruddy et al., 2004). To
determine whetherMCPIP1 impacts the IL-6 promoter, ST2 cellsmunity 43, 475–487, September 15, 2015 ª2015 Elsevier Inc. 477
Figure 2. MCPIP1 Inhibits IL-17-Mediated Pulmonary Inflammation in Zc3h12a+/– Mice
(A) Fibroblasts from Zc3h12a+/ mice or WT littermates were treated with LPS or IL-17 for 4 hr and MCPIP1 and b-tubulin assessed by immunoblotting (left) or
qPCR (right). Data expressed as fold-change versus untreated WT. *p < 0.05 versus IL-17-treated WT sample.
(B and C) WT or Zc3h12a+/mice (n = 5) were treated intranasally with 300 ng recombinant IL-17. 24 hr later, BALF was stained for Gr-1 and F4/80 and quantified
by flow cytometry. C = control unchallenged. *p < 0.05 compared to IL-17-treated WT mice.
(D) H&E-stained lung sections from the indicated mice are shown. Scale bars represent 200 mM.
(E) WT or Zc3h12a+/ mice (n = 2 for control, n = 5 for IL-17-treated) were treated intranasally with 500 ng IL-17. After 8 hr, levels of CXCL5 and CXCL1 in BALF
were assessed by ELISA. *p < 0.05 versus IL-17-treated WT mice. n.s., not significant.
Data are presented as mean ± SEM throughout. All experiments were performed a minimum of twice.were co-transfected with MCPIP1 and a luciferase reporter
driven by the IL-6 proximal promoter (Eickelberg et al., 1999).
MCPIP1 modestly suppressed IL-17-mediated activation of the
IL-6 promoter (15% reduction, Figure 5A), indicating that the
enhanced expression of IL-6 seen after MCPIP1 knockdown is
due mainly to Il6 transcript stabilization.
IL-17 also activates the Lcn2 promoter but does not promote
Lcn2 mRNA half-life (Shen et al., 2006). In contrast to the IL-6478 Immunity 43, 475–487, September 15, 2015 ª2015 Elsevier Inc.promoter, MCPIP1 strongly suppressed the Lcn2 promoter
(85%, Figure 5A). The baseline activities of the IL-6 and
Lcn2 promoters were also suppressed, consistent with the
inhibitory effect of MCPIP1 on tonic expression of these genes
(Figure 1). Because MCPIP1 is not a transcription factor, it was
unlikely that its activity on the Lcn2 promoter was direct. There-
fore, we evaluated the impact of MCPIP1 on signaling interme-
diates downstream of IL-17. MCPIP1 knockdown enhanced
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Figure 3. MCPIP1 Restrains IL-17-De-
pendent Responses to Candida albicans
Infection
(A) Zc3h12a+/ mice crossed to Il17ra/ mice (n =
5–8) and littermates were subjected to candidiasis
by i.v. injection of C. albicans. After 2 days, fungal
burdens in kidney were assessed by plating and
colony enumeration. *p < 0.05 versus WT. Data
pooled from two independent experiments.
(B) Survival curve of WT (solid line, n = 11) and
Zc3h12a+/ (dashed line, n = 10) mice after candi-
diasis. Data are pooled from two independent
experiments.
(C) Periodic acid Schiff (PAS)-stained kidney sec-
tions. Yellow boxes indicate location of higher
magnification images. Scale bars represent
1,000 mM (top) or 200 mM (bottom).
(D) WT or Zc3h12a+/ mice (n = 4–6) were infected
i.v. with C. albicans after administration of a-IL-6R
or isotype Abs. Fungal loads in kidney were
assessed 2 days after infection. *p < 0.05 versus
a-IL-6R-treatedWTmice. zp < 0.05 versus isotype-
treated WT mice.
Data presented as mean ± SEM throughout. All
experiments were performed a minimum of twice.expression of Nfkbiz (encoding IkBz) and Rel (encoding c-Rel)
at baseline and upon IL-17 stimulation (Figures 5B and S3).
There was no effect on other NF-kB components, C/EBPb,
C/EBPd, TAB2, or TAB3, consistent with the known activity of
MCPIP1 in T cells (Figure S3; Uehata et al., 2013). We postu-
lated that inhibition of IkBz expression by MCPIP1 might
explain its potent effect on Lcn2 promoter activation (Figure
5A; Karlsen et al., 2010). Indeed, co-expression of MCPIP1
with IkBz in HEK293T cells led to marked degradation of IkBz
(Figure 5C, lane 2), which required its 30 UTR (Figure 5C,
lane 4). To determine whether IkBz in turn regulated Lcn2,
ST2 cells were treated with siRNA against IkBz or MCPIP1
and treated with IL-17 for 3 hr. Knockdown of IkBz abrogated
induction of Lcn2 (Figure 5D), as well as other IL-17 target
genes, including Cxcl1, Cxcl5, and Ccl20 (Figure S4A). Accord-
ingly, MCPIP1 impairs activation of some IL-17-dependent pro-
moters through degradation of Nfkbiz.
MCPIP1 Degrades Inflammatory Receptor mRNA
USP25 and A20 temper IL-17 signaling by deubiquitinating
TRAF6 (Garg et al., 2013; Zhong et al., 2012), and MCPIP1
also possesses deubiquitinase (DUB) activity (Liang et al.,
2010). To determine whether MCPIP1 acts redundantly with
USP25 or A20, ST2 cells were transfected with siRNAs targeting
MCPIP1, A20, or USP25. Knockdown of MCPIP1 in combination
with A20 or USP25 led to increased induction of IL-6 compared
to knockdown of each inhibitor alone (Figures 6A and S5E), indi-
cating that they act by nonredundant mechanisms. Recently the
RNA binding proteins Roquin-1 and Roquin-2 were shown to
regulate Il6 (Jeltsch et al., 2014). As with A20 and USP25, we
saw an additive effect of knocking down both MCPIP1 and Ro-
quins on Il6 and Lcn2 mRNA, although not detectably for IL-6
protein, suggesting that they are not fully redundant in the IL-
17 pathway (Figure S4B).ImA20 and TRAF3 bind directly to the IL-17RA cytoplasmic tail to
limit signaling (Garg et al., 2013; Zhu et al., 2010). Consequently,
we askedwhetherMCPIP1 binds to the IL-17R.Myc-taggedmu-
rine (m)IL-17RA, mIL-17RC, or Act1 were expressed in HEK293T
cells with Flag-MCPIP1. Lysates were immunoprecipitated with
anti-Myc Abs and immunoblotted for Flag and Myc. Unexpect-
edly, co-expression ofMCPIP1with IL-17RA or IL-17RC resulted
in a strong, dose-dependent decrease in receptor expression
(Figures 6B, lanes 6–7, and 6C), making it impossible to deter-
mine whether MCPIP1 binds these subunits. In contrast, there
was no effect of MCPIP1 on expression of TRAF6, Act1, or
signaling-defective Act1 mutants (Figures 6B, lane 8, and S5A
and S5C). Transfection of MCPIP1 with TLR4 and TNFR2 also
diminished their expression (Figure S5B). To assess whether
the decrease in IL-17RA impacted its expression at the cell sur-
face, mIL-17RA and MCPIP1 were transfected into HEK293T
cells and mIL-17RA expression was evaluated by flow cytome-
try. Co-expression with MCPIP1 but not TRAF6 or A20 led to
reduced surface expression of mIL-17RA. An RNase-deficient
mutant of MCPIP1 (Liang et al., 2010) did not alter IL-17RA sur-
face expression (Figure 6D). To determine whether MCPIP1
downregulates IL-17RA by degrading its mRNA, MCPIP1, IL-
17R subunits, or Act1 were co-transfected in HEK293T cells.
Indeed, there was markedly reduced expression of Il17ra and
Il17rc mRNA but not Traf3ip2 (Act1) in the presence of MCPIP1
(Figure 6E).
The observation that MCPIP1 degrades IL-17R transcripts
was surprising, because they lack prototypical destabilizing
AU-rich elements (AREs) in the 30 UTR. We therefore mapped
the target sequence needed for degradation with a series of
IL-17RA mutants (Figures S6A–S6C). A mIL-17R construct con-
taining the first 775 nucleotides (258 amino acids) was subject
to MCPIP1 degradation, whereas a mutation with just the first
600 nucleotides was not (Figure 6F). Consistently, a mIL-17RAmunity 43, 475–487, September 15, 2015 ª2015 Elsevier Inc. 479
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Figure 4. MCPIP1 Limits IL-17-Dependent
Autoimmune CNS Pathology
(A) The indicated mice (n = 13–17) were subjected
to EAE and clinical scores assessed daily (left). The
percentage of mice exhibiting EAE symptoms is
indicated (right). Data are pooled from two exper-
iments. Data are presented as mean clinical score
of all mice. *p < 0.05 by ANOVA and Student’s
t test.
(B) Gene expression in spinal cords wasmeasured
by qPCR normalized to Gapdh.
Data presented as mean ± SEM throughout.construct with an internal deletion spanning this sequence (IL-
17RAD200–258) was largely, though not completely, resistant
to degradation, observed at both mRNA and protein levels (Fig-
ure 6F). Thus, MCPIP1 degrades Il17ra through amotif located in
its 50 coding region.
To show that MCPIP1 degraded Il17ra mRNA directly, His-
tagged MCPIP1 was purified from transfected HEK293T cells
(Figure S6D). RNAs encoding the Il6-30 UTR or Il17ra (bases 1–
775, as in Figure 6F) were generated in vitro, co-incubated for
1 hr with purified MCPIP1, and visualized on denaturing agarose
gels (Figure 6G). The Il6-30UTR and Il17ra transcripts were effi-
ciently degraded by MCPIP1, but Traf3ip2 mRNA (Act1) was
resistant to degradation (Figure S6E). There was reduced migra-
tion of all residual transcripts in lanes where purified MCPIP1
was added, suggesting that MCPIP1 binds directly to mRNA.
Because Traf3ip2mRNA also showed slower migration, binding
of MCPIP1 to a putative target might be insufficient to drive sub-
strate degradation. To determine whether a decrease in Il17ra
mRNA occurred in vivo, Il17ra was assessed in spinal cords
of mice subjected to EAE, a setting where dynamic regulation
of IL-17RA has been reported (Liu et al., 2014a). Expression of
Il17ra mRNA was indeed enhanced, albeit modestly, in
Zc3h12a+/ spinal cord homogenates compared to Zc3h12a+/+
(Figure S6F). We confirmed by flow cytometry that IL-17RA sur-
face expression was induced in microglia during EAE, which had
not been previously shown. However, there was no detectable
elevation of IL-17RA in Zc3h12a+/ compared to Zc3h12a+/+ mi-
croglia (Figure S6G). Collectively, these data show that MCPIP1
has the capacity to degrade Il17ra mRNA through its 50 coding
sequence. Although IL17ra mRNA was elevated in Zc3h12a+/
spinal cords during EAE, there was no apparent impact on IL-
17RA surface expression, indicating that this phenomenon prob-
ably does not account for the enhanced susceptibility to EAE in
Zc3h12a+/ animals.
We next sought to delineate the MCPIP1 domain required to
mediate mRNA degradation (Figure 7A). Mutants of human
MCPIP1 in the RNase domain (D225/226A and D141N), a
zinc finger (ZnF) domain deletion (DZF), or a point mutation within
the ZnF (C306R) were co-expressed with mIL-17RA in HEK293T480 Immunity 43, 475–487, September 15, 2015 ª2015 Elsevier Inc.cells, and IL-17RA was assessed by
immunoblotting. As expected, ZnF mu-
tants of MCPIP1 failed to induce IL-
17RA degradation (Figure 7B, lanes 1, 3,
5). The ZnF is required for both RNase
and DUB activity (Liang et al., 2010), but
a DDUB domain mutant (Kapoor et al.,2015) degraded IL-17RA similarly toWT (Figure 7C, lane 3). Simi-
larly, degradation of IkBz occurred independently of the DUB
domain (Figure 7D). Zc3h12a/ fibroblasts reconstituted with
WT but not ZnF-deficient MCPIP1 (C306R) showed impaired
IL-17-induced IL-6 production (Figure 7E). These data confirm
that the RNase activity of MCPIP1 regulates IL-17-dependent
signaling. Because ZnF-deficientMCPIP1mutants did not cause
IL-17RA degradation, we re-visited the question of whether
MCPIP1 and IL-17RA proteins interact directly by co-transfect-
ing IL-17RA with MCPIP1.DZF and MCPIP1.D225/226A. How-
ever, there was no apparent association of MCPIP1 with IL-
17RA (Figure S5D). Thus, unlike A20 or TRAF3 (Garg et al.,
2013; Zhu et al., 2010), MCPIP1 does not directly engage the
IL-17R, but rather targets downstream mRNA transcripts for
degradation.
DISCUSSION
IL-17 is vital for controlling fungal and bacterial infections, both in
mice and humans (Milner and Holland, 2013). IL-17 exerts its
host-protective activity by upregulating antimicrobial peptides,
cytokines, and chemokines as well as transcription factors that
regulate those genes (Onishi and Gaffen, 2010). Conversely,
IL-17 inhibition limits collateral damage stemming from IL-17-
induced inflammation, which is key to controlling autoimmunity.
This concept is being exploited clinically with biologics targeting
IL-17, the IL-17R, or Th17 cells (Gaffen et al., 2014).
To identify new signaling molecules that regulate the IL-17
pathway, we mined published data comparing IL-17R-depen-
dent gene expression in the context of Candida infection (Conti
et al., 2009), thereby identifying Zc3h12a as an IL-17 target
gene. MCPIP1 was originally discovered as a target of MCP-1
and is upregulated by many inflammatory stimuli (Dhamija
et al., 2013; Sønder et al., 2011). IL-17 regulates Zc3h12a
through Act1-mediated activation of NF-kB and IKKg as well
as through mRNA stabilization (Somma et al., 2015; Sønder
et al., 2011). MCPIP1 belongs to a family of CCCH zinc finger
proteins that exhibit RNase activity against inflammatory and
viral mRNA transcripts (Uehata and Akira, 2013; Xu et al.,
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Figure 5. MCPIP1 Differentially Regulates
IL-17 Target Promoters and Transcription
Factors
(A) ST2 cells were transfected with varying doses
of MCPIP1 plasmid (0–300 ng) together with Luc
reporters driven by the IL-6 or Lcn2 promoters.
Cells were treated ± IL-17 for 8 hr and Luc activity
assessed in triplicate. Data presented relative to
the unstimulated control without MCPIP1. *p <
0.05 versus unstimulated sample of the corre-
sponding condition.
(B) ST2 cells were transfected with siRNAs against
MCPIP1, stimulated ± IL-17 for 3 hr, and analyzed
for expression of the indicated genes by qPCR.
*p < 0.05 versus unstimulated. zp < 0.05 versus IL-
17-treated control siRNA.
(C) HEK293T cells were transfected with
MCPIP1 ± constructs expressing IkBz with or
without its 30 UTR. Whole cell lysates were
analyzed by immunoblotting for IkBz (top),
MCPIP1 (middle), or b-tubulin (bottom).
(D) Top: Murine Lcn2 promoter construct. Bottom:
ST2 cells were transfected with siRNAs targeting
IkBz, MCPIP1, or a scrambled control, treated ±
IL-17 for 3 hr, and the indicated genes evaluated
by qPCR. Data expressed as fold-change relative
to the untreated control siRNA. *p < 0.05 versus
control siRNA sample treated with IL-17. zp < 0.05
versus MCPIP1 siRNA treated with IL-17.
Data presented as mean ± SEM throughout. Ex-
periments were performed a minimum of twice.2012). Additionally, MCPIP1 inhibits TLR4 signaling by deubiqui-
tinating TRAFs (Liang et al., 2010). Because IL-17 shares over-
lapping activation mechanisms and target genes with TLRs,
we postulated that MCPIP1 might inhibit the IL-17 pathway.
RNA silencing and reconstitution of Zc3h12a/ cells confirmed
this hypothesis, which was further supported in a variety of IL-
17-dependent in vivo models. MCPIP1 thus joins the ranks of
A20 andmiR-23b as negative feedback regulators of IL-17 signal
transduction.
In contrast to its DUB functions in blocking TLR activation, only
the RNase activity of MCPIP1 seems to be critical in blocking
IL-17 signals. Control of mRNA half-life is an essential but often
overlooked facet of immune homeostasis (Hamilton et al., 2010).
IL-17 promotes stability of many inflammatory gene transcripts,
best studied for Cxcl1 (Datta et al., 2010). IL-17-induced stabili-
zation of Cxcl1 occurs through Ikki-induced phosphorylation of
Act1. In turn, phosphorylated Act1 binds TRAF2 and TRAF5,
which sequester the RNA binding protein SF2 to allow binding
of the mRNA-stabilizing factor HuR (Bulek et al., 2011; Herjan
et al., 2013; Sun et al., 2011). IL-17, in cooperation with TNFa,
promotes Il6 mRNA stability, mediated in part through MAPK
(Shimada et al., 2002; Tokuda et al., 2004). Here we show that
MCPIP1, via its RNase activity, controls expression of a variety
of IL-17-induced genes. Although some of this regulation might
be through direct action on target transcripts (e.g., Il6), certain
IL-17 target genes such as Lcn2 are regulated through their pro-
moters, which we show occurs indirectly viaNfkbiz. It is possible
that microRNAs or regulation of other signaling intermediates
such as c-Rel might additionally contribute to the activity of
MCPIP1 in the IL-17 cascade, similar to recent findings for regu-Imlation of A20 by miR-873 (Liu et al., 2014b). However, MCPIP1
inhibits DICER, affecting miR biogenesis nonspecifically
(Suzuki et al., 2011). miR-23b inhibits IL-17 signaling by degrad-
ing TAB2/3 and IKKa (Zhu et al., 2012); therefore, inhibition of
DICER would be expected to decrease miR-23b, leading to
increased expression of NF-kB-dependent genes such as Il6
and Lcn2. Because we see the opposite effect of MCPIP1 on
these genes, it is unlikely that the miR-23b pathway is a target
of MCPIP1.
MCPIP1 regulates tonic inflammation and is vital for main-
taining immune homeostasis in vivo. Consequently, Zc3h12a/
mice suffer from fatal multi-organ inflammation (Liang et al.,
2010; Matsushita et al., 2009). This effect is attributed to TLR
signaling from gut microbiota, because antibiotics extend
Zc3h12a/ lifespan (Huang et al., 2013; Liang et al., 2010,
2011; Miao et al., 2013). We generated Zc3h12a/Il17ra/
double knockout mice that were not rescued from systemic
inflammation or early death, indicating that IL-17 is not a major
driver of spontaneous hyperinflammation (data not shown). In
contrast, Zc3h12a+/ mice did not exhibit early death or sys-
temic inflammation in visceral organs. Zc3h12a+/ mice showed
reduced expression of MCPIP1 after stimulation with LPS or IL-
17; thus, the impact of MCPIP1 haploinsufficiency apparently
manifests mainly in inflammatory conditions.
Inflammation controlled by MCPIP1 is also linked to enhanced
T cell activation and subsequent impairment of Th17 cell devel-
opment (Gewies et al., 2014; Jeltsch et al., 2014; Uehata et al.,
2013). In T cells, inhibitory activity is constitutive, as MCPIP1 is
cleaved by MALT1 upon TCR activation, relieving its checkpoint
activity (Jeltsch et al., 2014; Mino et al., 2015). However,munity 43, 475–487, September 15, 2015 ª2015 Elsevier Inc. 481
00.5
1.0
1.5
Fo
ld
C
ha
ng
e
Il17ra
IL17ra
(1-775)
+-MCPIP1
*
Il17ra IL17ra
(Δ600-775)
+ +--
Il17ra
*
*
F
0
0.5
1.0
1.5
Fo
ld
C
ha
ng
e
MCPIP1
Il17ra Traf3ip2 (Act1)Il17rc
Vector MCPIP1Vector MCPIP1Vector
*
*
Transfection:
1 2 3 4 5 6 7 8
Act1-Myc
IL-17RC-Myc
IL-17RA-Myc
EV
IB: Myc
IB: Flag
+
+
+
+
MCPIP1-Flag + + + +
+
+
+
+
-
-
-
-
-
-
-
-
- -
-
-
- -
-
- -
-
- - -
-
-
-
-
-
--
Act1
MCPIP1
IL-17RA or
IL-17RC IP: Myc
IP: Myc
C
MCPIP1
IL-17RA + + + + + + +
MCPIP1
Myc
(IL-17RA)
2 3 4 5 61 7
D
E
2° Ab Vector A20MCPIP1
IL-17RA
IL
-6
(n
g/
m
l)
2
0
4
6
siRNA: Control USP25 A20 MCPIP1 A20+
MCPIP1
USP25+
MCPIP1
*
Untreated
IL-17 *
‡
** **
‡
‡
‡
A
ST2 Cells
B
G
H 2
O
Bu
ffe
r
MC
PI
P1
Il6
3' UTR
IL17ra
(1-775)
Bu
ffe
r
MC
PI
P1
M
ar
ke
r
200
500
1000
1500
2000
3000
4000
6000
MC
PI
P1
MC
PI
P1
ΔZ
F
A2
0
TR
AF
6
Ve
cto
r
M
FI
R
at
io
(S
am
pl
e/
Ve
ct
or
)
1.4
1.2
1.0
0.8
0.6
MCPIP1
ΔZF
TRAF6
MCPIP1
IL-17RA
+ +
IL-17RA
Δ200-258
- -
2 3 41
Myc
(IL-17RA)
MCPIP1
Tubulin
IL17ra
(1-600)
+-
IL17ra
(1-500)
+-
Figure 6. MCPIP1 Induces Degradation of IL-17R Subunit but Not Act1 mRNA Transcripts
(A) ST2 cells were transfected with indicated siRNAs, treated ± IL-17 for 3 hr, and analyzed for IL-6 by ELISA. *p < 0.05 versus IL-17-treated control siRNA. zp <
0.05 versus unstimulated control. Data presented as mean ± SEM.
(legend continued on next page)
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Figure 7. Degradation of IL-17RA by MCPIP1 Requires RNase but Not DUB Activity
(A) Diagram of MCPIP1 subdomains. Residue designations are for the human homolog. Abbreviations are as follows: UBA, ubiquitin association domain; NYN,
Nedd4-BP1, YacP nuclease; ZF, zinc finger; DUB, deubiquitinase domain; PRR, proline-rich region.
(B and C) HEK293T cells were transfected with plasmids encoding human MCPIP1 or mutants with Myc-tagged murine IL-17RA. After 24 hr, whole cell lysates
were immunoblotted for Myc (top) and MCPIP1 (bottom).
(D) HEK293T cells were transfected with IkBz with a 30 UTR with MCPIP1 and the indicated mutants. Lysates were analyzed by immunoblotting for IkBz (top),
MCPIP1 (middle), or b-tubulin (bottom). Note that the DDUB mutant (D371–385) is GFP-tagged and migrates as a larger band.
(E) Zc3h12a/ cells were transfected with vector, MCPIP1, or theMCPIP1.C306Rmutant. Cells were treated with IL-17 for 3 hr. IL-6 was assessed by ELISA and
Il6 assessed by qPCR. *p < 0.05 versus IL-17-treated vector control. zp < 0.05 versus unstimulated vector control. n.s., not significant.
Data presented asmean ±SEM throughout. Data expressed as fold-change relative to untreated vector control. Experimentswere performed aminimumof twice.because CD4-specific Zc3h12a-knockout mice survive signifi-
cantly longer than those with a complete MCPIP1 deficiency,
MCPIP1 evidently functions in both T cells and non-T cell types.
In this regard, IL-17 signaling occurs dominantly in non-hemato-
poietic cells. In contrast to the TCR pathway, MCPIP1 is induced
during IL-17R signaling to act as a break. Thus, MCPIP1 restricts(B) HEK293T cells were transfected with murine Flag-tagged MCPIP1 together w
immunoprecipitated with anti-Myc Abs and immunoblotted for Myc and Flag. Ar
(C) HEK293T cells were transfected with varying concentrations of Flag-MCPIP1
(D) Left: HEK293T cells were transected with mIL-17RA and the indicated genes (
APC-tagged a-IL-17RA Abs and APC-tagged 2 Ab. Right: MFI within IL-17RA+ g
Data for two independent experiments is shown.
(E) HEK293T cells were transfected with MCPIP1 and the indicated constructs. A
relative to vector-transfected controls. *p < 0.05 versus corresponding samples
(F) HEK293T cells were transfected with MCPIP1 and the indicated IL-17RA mut
change relative to Il17ra(1-775)-transfected control. *p < 0.05 versus correspondin
constructs. Left: After 24 hr, mRNAwas assessed as in (E). Right:Whole cell lysate
mutant in the right panel represent amino acids.
(G) In vitro transcribed mRNAs encoding Il6 30 UTR or Il17ra (nucleotides 1–775
Transcripts were analyzed on a denaturing agarose gel. Panels are derived from
Data presented as mean ± SEM throughout.
Imboth IL-17 production in lymphocytes through inhibition of TCR
signaling and IL-17 responsiveness in non-hematopoietic cells
by virtue of its role as a feedback inhibitor.
TRAF3 and A20 bind to IL-17RA at a domain associated with
negative feedback regulation (Garg et al., 2013; Zhu et al.,
2010). In assessing whether MCPIP1 associates with IL-17RAith Myc-tagged murine IL-17RA, IL-17RC, and Act1. After 24 hr, lysates were
rows indicate IL-17RA, IL-17RC, or Act1.
with Myc-IL-17RA. Lysates were immunoblotted for Myc or Flag.
vector, A20, TRAF6, MCPIP1, MCPIP1DZF). After 24 hr, cells were stained with
ates, depicted as the ratio of the MFI of each sample relative to vector control.
fter 24 hr, mRNA was assessed by qPCR. Data are expressed as fold-change
without MCPIP1.
ants. After 24 hr, mRNA was assessed by qPCR. Data are expressed as fold-
g samples without MCPIP1. HEK293T cells were transfected with the indicated
swere analyzed by immunoblotting as in (B). Note that the numbers used for the
) were incubated with water, buffer, or recombinant MCPIP1 for 1 hr at 30C.
the same gel image.
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and IL-17RC, we made the unexpected observation that
MCPIP1 instead triggered their degradation, driven at the level
of mRNA expression. MCPIP1 degrades Il6 through its 30 UTR
(Matsushita et al., 2009), which we also demonstrate for Nfkbiz
(encoding IkBz). Similarly, MCPIP1 targets c-Rel and Il2 via
the 30 UTR (Li et al., 2012; Uehata et al., 2013). In contrast,
the minimal Il17ra sequence targeted by MCPIP1 is located in
the 50 region of its mRNA. Because MCPIP1 also targets
TNFR and TLR4, MCPIP1 might limit inflammatory signaling
via degradation of inflammatory receptors. Regulation of
mRNA stability might provide a potential therapeutic avenue
for diseases where IL-17 activity is relevant. For example,
chlorpromazine hydrochloride, an anticholinergic agent
commonly used as an antipsychotic drug, inhibits LPS-induced
IL-6 by blocking Arid5a, an RNA binding protein that stabilizes
the Il6 transcript (Masuda et al., 2013).
Although the finding that MCPIP1 degrades Il17ra was
intriguing, we have not yet identified a setting where IL-17RA
expression is decreased in vivo. Generally, Il17ramRNA turnover
is low, due in part to the absence of destabilizing sequences in
the 30 UTR, and it is likely that subsequent translation is also at
a low steady-state level. MCPIP1 was recently shown to act
primarily on transcripts undergoing active translation (i.e., in
polysomes) (Mino et al., 2015). Only a few studies have reported
dynamic regulation of IL-17RA; we and others showed that IL-
17RA on T cells is induced by IL-21 and IL-15 (Lindemann
et al., 2008; Zeng et al., 2005). IL-17RAwas also shown to be up-
regulated in neuroglial cells in vitro after immunization with CFA
(Liu et al., 2014a), which we confirmed in vivo in this study.
Despite evidence for increased Il17ra transcript levels in spinal
cord, surface IL-17RA levels did not seem to be affected, indi-
cating that this mechanism probably does not account for the
enhanced pathology in Zc3h12a+/ mice. However, Zc3h12a/
mice have elevated levels of IL-17A due to enhanced Th17 cell
differentiation, and IL-17RA internalizes upon IL-17 signaling
(Jeltsch et al., 2014; Lindemann et al., 2008); one could specu-
late that elevated IL-17RA was not observed in Zc3h12a+/
mice because its surface expression is offset by accelerated
ligand-mediated internalization. Moreover, we did not evaluate
IL-17RC levels in this study, nor can we rule out the possibility
that there might be a transient change in IL-17RA expression
at a time point that was not analyzed here. Similarly, we do not
knowwhether changes in IL-17RA expression occur in other dis-
ease settings such as candidiasis. Certainly this topic warrants
further investigation.
Emerging studies have revealed multiple checkpoints of IL-
17 signaling. A20 and USP25 downregulate TRAF6, limiting
NF-kB and MAPK activation (Garg et al., 2013; Zhong et al.,
2012). C/EBPb exerts negative effects on IL-17-dependent
gene expression (Shen et al., 2009), and TRAF3 and TRAF4
block Act1 binding to the IL-17R or TRAF6, respectively (Gaffen
et al., 2014; Zepp et al., 2012; Zhu et al., 2010). It is unclear why
so many non-redundant mechanisms are invoked to constrain
IL-17, but the requirement for multiple, concerted checkpoints
in inflammation has been observed in numerous innate immune
settings (Carpenter et al., 2014). One reason might relate to
the kinetics of each inhibitor, permitting control at different
stages after signal initiation. Although A20 and MCPIP1 are
both induced by IL-17, their expression kinetics are dissimilar484 Immunity 43, 475–487, September 15, 2015 ª2015 Elsevier Inc.(Garg et al., 2013). IkBa and A20 both inhibit NF-kB, but math-
ematical modeling of the TNFa pathway revealed that IkBa re-
stricts activation of the first phase of NF-kB activation, whereas
A20 controls the second phase (Werner et al., 2008). The appli-
cation of computational modeling to the IL-17 pathway might
lend insight into how negative regulatory signals are functionally
integrated.
In summary, MCPIP1 negatively regulates signaling down-
stream of IL-17 on multiple fronts. One mechanism is through
destabilization of Il6 mRNA. IL-6 contributes to IL-17 activity in
many settings, including candidiasis and EAE (Basu et al.,
2008; Samoilova et al., 1998). However, not all the effects of
MCPIP1 occur through regulation of IL-6 (Uehata et al., 2013).
MCPIP1 also limits expression of effectors such as IkBz that
function positively in driving IL-17-dependent gene expression.
Additionally, we uncovered a previously unrecognized capacity
of MCPIP1 to degrade certain mRNA transcripts in a 30 UTR-in-
dependent manner, including receptors such as the IL-17R and
TLR4, although the relative importance of receptor regulation
compared to MCPIP1’s other activities so far appears to be min-
imal. The cumulative impact of MCPIP1 on these signaling effec-
tors, and likely others yet to be discovered, results in a marked
and biologically important constraint of IL-17-mediated signal
transduction.
EXPERIMENTAL PROCEDURES
Cell Culture
ST2, primary fibroblasts, and HEK293T cells were cultured in a-MEM (Sigma)
with 10% FBS, L-glutamine, and antibiotics (Invitrogen). OKF6-TERT2 cells
(Dickson et al., 2000) were provided by J. Rheinwald (Brigham & Women’s
Hospital) cultured in Serum-Free Fibroblast media, 25 mg/ml Bovine Pituitary
Extract, and 2 mg/ml EGF (Life Technologies). HEK293T cells were transfected
by CaPO4. ST2 and 1
 fibroblasts were transfected with Fugene 6 or Fugene
HD (Promega). IL-17 was from Peprotech and used at 100–200 ng/ml.
siRNA, Plasmids, and Luciferase Assays
ON-TARGETplus SMARTpool siRNAs were from Dharmacon. ST2 cells
were transfected with 50 nM siRNA using DharmaFECT Reagent 1 (Dharma-
con). Plasmids encoding mIL-17RA, IL-17RC, MCPIP1, and mutants were
described (Kapoor et al., 2015; Liang et al., 2010; Maitra et al., 2007; Shen
et al., 2009). IkBz with 30 UTR was provided by U. Siebenlist (NIH). The
DDUB mutant (GFP-tagged) lacks residues 371–385 and retains full RNase
and anti-Dicer activities. Luciferase assays were performed as described
(Shen et al., 2006).
RNA Isolation and qPCR
RNA was isolated with RNeasy Mini Kits (QIAGEN). cDNA was generated with
Superscript III First Strand kits (Invitrogen). Genes were measured by real-time
RT-PCR (qPCR) using SYBR Green FastMix ROX (Quanta Biosciences) on a
7300 Real Time instrument (Applied Biosystems). Expression was normalized
to Gapdh. Primers were from Super Array Biosciences or QuantiTect Primer
Assays (QIAGEN).
ELISA, Immunoprecipitations, Histology, Flow Cytometry
Immunoblotting and immunoprecipitations were performed as described (Ho
et al., 2010; Maitra et al., 2007). Antibodies a-A20, a-myc, and a-IkBz were
from Cell Signaling; a-MCPIP1, a-TRAF6, and a-Act1 from Santa Cruz
Biotechnology; and a-HA and a-FLAG from Sigma. Blots were developed
with a FluorChem E imager (Protein Simple). Abs against IL-17RA were from
Amgen (clone M751). ELISA kits were from eBioscience. Histology was per-
formed by the University at Buffalo Histology Core and imaged on an EVOS
FL microscope system (Life Technologies). For flow cytometry, CNS cells
were stained with Abs from eBioscience or BD and analyzed on a FACS For-
tessa with FlowJo (Tree Star).
Protein Purification and In Vitro RNA Degradation
For expression, 7.5 3 106 HEK293T cells were transfected with His-MCPIP1
(human). 48 hr later, cells were sonicated in 50 mM Tris-HCl (pH 8.3)/10%
glycerol, 20 mM imidazole, 5 mM b-mercaptoethanol, and protease inhibitor
cocktail (Calbiochem). Lysates were centrifuged at 15,000 rpm for 30 min
and passed over an imidazole gradient using HiTrap chelating HP (GE
Healthcare) charged with Ni sulfate. Fractions were dialyzed against
50 mM Tris-HCl (pH 8.3)/150 mM NaCl/3 mM DTT and concentrated with
Amicon Ultra centrifugal units-30K (Millipore). MCPIP1 was confirmed in
fractions by immunoblotting with a-His. RNAs encoding IL-17RA (1–775),
Act-1, or IL-6 30 UTR (2 mg) in the pCR2.1 vector were synthesized with
TranscriptAid T7 High Yield Transcription Kits (Thermo Scientific). Tran-
scripts were incubated with MCPIP1 (2 mg) in 25 mM HEPES, 50 mM po-
tassium acetate, 5 mM DTT, and RNasin (40 U) (Promega) for 1 hr at 30C.
RNA was analyzed on denaturing 1% agarose (Lin et al., 2013, 2014; Mat-
sushita et al., 2009).
Mice
Mice were age and sex matched on the C57BL/6 background. WT mice were
from The Jackson Laboratory. In experiments with Zc3h12a+/ mice, litter-
mates were used. Il17ra/ were from Amgen and bred in-house. Protocols
were approved by the University of Pittsburgh IACUC and adhered to guide-
lines in the Guide for the Care and Use of Laboratory Animals of the NIH.
Intranasal IL-17 Delivery
Mice were treated intranasally with carrier-free IL-17 (R&D Systems) (300–
500 ng). BALF was obtained with 0.5 ml PBS/0.5 mM EDTA followed by a
4 ml lavage. Supernatants from first lavage were used in ELISA and harvests
combined for FACS. Cells were stained with a-CD11b (BD), a-Gr-1 (Bio-
Legend), and a-F4/80 (eBiosciences). Left lobe of lung was used for qPCR.
Flow cytometry was performed on a Becton Dickinson LSR II and analyzed
by FlowJo (Tree Star).
Candidiasis
Oral candidiasis was performed by sublingual inoculation of C. albicans
(CAF2-1) for 75 min (Conti et al., 2009). RNA was prepared from tongue by
dissociation on a GentleMACS with M-tubes (Miltenyi Biotec). For systemic
candidiasis, mice were injected i.v. with 1-2 3 105 C. albicans yeast cells in
100 ml PBS. Kidney was homogenized in C-tubes in 2 ml PBS and plated on
YPD-AMP. Anti-IL-6R Abs from Genentech were used at 20 mg/kg on days
2, 1, and +1 relative to infection.
Experimental Autoimmune Encephalomyelitis
Female mice were immunized subcutaneously in 4 sites on the back with
100 mgmyelin oligodendrocyte glycoprotein (MOG) peptide (aa 35–55) emulsi-
fied with Complete Freund’s Adjuvant with 1 mgM. tuberculosis strain H37Ra
(DIFCO). Mice received 100 ng pertussis toxin (List Biological Laboratories) i.p.
on day 0. Mice were assessed daily by blinded assessors and scored as fol-
lows: 1, flaccid tail; 2, impaired righting reflex and hindlimbweakness; 3, partial
hindlimb paralysis; 4, complete hindlimb paralysis; 5, hindlimb paralysis with
partial forelimb paralysis; 6, moribund.
Statistics
Data were analyzed by Kaplan-Meier, ANOVA, Mann-Whitney, or unpaired
Student’s t test by GraphPad Prism.
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